Category: Prohost Letters
During the Departed Week
The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week Highs The three picks referred to in the above title are, Novartis (NVS), Array (AARY) and Ionis (IONS) . Previous Prohost Letters discussed Novartis...
Read More
March 19, 2019
0
Prohost Letter #412 Part 3
Prohost Letter #412 Part 3 GLIOBLASTOMA - Is There Hope? Senator John McCain was diagnosed with a malignant brain tumor, glioblastoma – the most common and aggressive form of brain cancer. The cancer is so aggressive that most surgeries did...
Read More
August 3, 2017
0
Prohost Letter #412 Part 2
Prohost Letter #412 Part 2 Living Breakthroughs in The Making - Understanding the origin of diseases or the reasons for their resistance and devastation is the road towards designing the right treatments. Research published about novel approaches or new entity...
Read More
July 27, 2017
0
Prohost Letter #412 Part 1
Prohost Letter #412 Part 1 Updating Our Targets - This Letter will be of three parts. The first part (today’s issue)aims at presenting our adjusted targets based on current news and updates related to the Prohost picks. A Case in...
Read More
July 24, 2017
0
Gilead's Acquisition Effect on Other CAR-T Developers' Stocks
Coming Soon... The Week in Review #3 Gilead Acquisition - Rallying by Association - Improving on Cancer Treatments... ...
Read More
September 4, 2017
0
Prohost Letter #430
Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary endpoints? How did the drugs respond as compared to placebo; what is the disability index, clinical remission, disease activity rate and safety results? What’s...
Read More
April 5, 2019
0
Three important news
The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across a lot of news announcing research, clinical trial results, collaborations, product approvals and acquisitions. Much of the departed week’s news though, does not represent...
Read More
September 25, 2018
0
The Week in Review #40
Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' ( GILD ) announcement at EASL? What is Gilead doing to find effective treatments for NASH? Why would Novo Nordisk's ( NVO ) anti-diabetes GLP-1 receptor drug...
Read More
April 16, 2019
0
Outperformance, Underperformance and Volatility
The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY AFTER AMGEN AND TEVA In less than five months, the FDA approved three products belonging to four drug developers – all targeting calcitonin gene-related...
Read More
October 2, 2018
0
Some Small Outperforming Biotech Firms
The Week in Review #4 AMAZING STOCK REBOUNDING - We have already witnessed and wrote about the fierce rebounding of some of our selected stocks comprising: Exelixis (EXEL), Sangamo (SGMO), Array (ARRY), ImmunoGen (IMGN) and others... ...
Read More
September 18, 2017
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)